Rubella Vaccine

Jagdish Kathwate
MD Pediatrics. Assistant Professor, Government Medical College, Aurangabad, India.
First Created: 01/10/2001  Last Updated: 08/01/2015

Patient Education

What is Rubella vaccine?

Rubella vaccine is available either as a single antigen vaccine or combined with measles and mumps (MMR). It contains live attenuated RA 27/3 strain of rubella virus, propagated in human diploid cells.

What is efficacy of RA 27/3 Rubella vaccine

It is highly efficacious. In clinical trials, 95%-100% of susceptible individuals aged 12 months or above-developed rubella antibodies by 3-4 weeks after vaccine administration. Vaccine-induced immunity is generally lifelong.

What is ideal Age of administration?

Rubella vaccine is usually given at age 12-15 months, but can also be administered to children as young as 9 months of age. It may also be administered to older children, adolescents, students, childcare personnel, health care workers, military personnel, and adult men in contact with women of childbearing age.

What are Contraindications for rubella vaccine?

History of anaphylactic reaction to neomycin or an anaphylactic reaction after a previous dose of rubella.

Advanced immunodeficiencies e.g. congenital immune disorders, malignancies, and immunosuppressive therapy.

What are Adverse events of rubella vaccine?

They are generally mild. Common symptoms are pain, redness, and induration at the site of injection, low-grade fever, rash, lymphadenopathy, myalgia & parasthesia.

What is Need for rubella vaccine?

The primary purpose of rubella vaccination is to prevent the occurrence of congenital rubella infection, which is an important cause of deafness, blindness, and mental retardation in the child affected.

1. Vijayalakshmi P, Anuradha R, Prakash K et al. Rubella serosurveys at three Aravind Eye Hospitals in Tamil Nadu, India. Bull World Health Organ. 2004;82(4):259-64.
2. Yadav S, Thukral R, Chakarvarti A. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age. Indian J Med Res. 2003;118:183-6.
3. Aksit S, Egemen A, Ozacar T et al. Rubella seroprevalence in an unvaccinated population in Izmir: recommendations for rubella vaccination in Turkey. Pediatr Infect Dis J. 1999;18(7):577-80.
4. Su SB, Guo HR. Seroprevalence of rubella among women of childbearing age in Taiwan after nationwide vaccination. Am J Trop Med Hyg. 2002;67(5):549-53.
5. Karakoc GB, Altintas DU, Kilinc B et al. Seroprevalence of rubella in school girls and pregnant women. Eur J Epidemiol. 2003;18(1):81-4.
6. Bukbuk DN, el Nafaty AU, Obed JY. Prevalence of rubella-specific IgG antibody in non-immunized pregnant women in Maiduguri, north eastern Nigeria. Cent Eur J Public Health. 2002 ;10(1-2):21-3.
7. Bhaskaram P, Ramalakshmi BA, Raju LA et al. Need for protection against rubella in India. Indian J Pediatr. 1991;58(6):811-4.
8. Chan PK, Li CY, Tam JS et al. Rubella immune status among healthcare workers in the Department of Obstetrics and Gynaecology of a regional hospital in Hong Kong: the need for a vaccination policy. J Hosp Infect. 1999;42(3):239-42.
9. Palihawadana P, Wickremasinghe AR, Perera J. Seroprevalence of rubella antibodies among pregnant females in Sri Lanka. Southeast Asian J Trop Med Public Health. 2003;34(2):398-404.
10. Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS. Bull World Health Organ. 1997;75(1):55-68.
11. Core information for the development of Immunization Policy. WHO- Vaccines and Biologicals. 2002 Update.

Rubella Vaccine Rubella Vaccine 2015-08-01
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0